The FDA has approved sirolimus protein-bound particles for injectable suspension (albumin-bound) (Fyarro™, Aadi Bioscience) for patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor. "Malignant perivascular epithelioid cell tumor is a rare, aggressive sarcoma," wrote Andrew J. Wagner, MD, PhD, Medical Director of Ambulatory Oncology at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School, and colleagues, in t...
Making Strides in Breast Cancer Treatment With Richard Zelkowitz, MD
Richard Zelkowitz, MD.
Significant progress has been made in numerous facets of breast cancer care in recent years, including developments in treatment, imaging, pathology, radiation, and surgery. In this interview, Dr. Richard Zelkowitz, a Regional Medical Director of the Breast Program at Hartford HealthCare, highlights the advances that have been made and explains the importance of subspecialties in ensuring that patients with breast cancer receive the most individualized care possible.
Virtual Tumor Board Improves Nurses’ Knowledge of Myelodysplastic Syndromes
An educational activity designed by i3 Health has demonstrated significant learning gains in the treatment and management of myelodysplastic syndromes (MDS) and has been presented at the 2021 Greater Los Angeles Oncology Nursing Society (GLAONS) Onco...
The outcomes of patients with lung cancer have improved significantly in recent years, largely due to the treatment targeting the cancer's specific genetic profile and the impact of immunotherapy, often in different groups of patients. In this interview, Ross Camidge, MD, PhD, Director of Thoracic Oncology at the University of Colorado Cancer Center, discusses the importance of considering multiple factors when deciding on clinical trials for patients. Oncology Data Advisor: When would you recom...
Valerie Brutus, MD, FACS.
For patients with breast cancer, the approach to treatment requires an individualized approach accounting for factors such as genetic risk, symptom management, and more recently, the challenges of the COVID-19 pandemic. In this interview, Dr. Valerie Brutus, a breast surgical oncologist at St. Vincent's Medical Center of Hartford HealthCare, discusses strategies for successfully incorporating each of these factors into patients' treatment.
The FDA has approved pembrolizumab (Keytruda®, Merck) for the adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy with resection of metastatic lesions."Patients with renal cell carcinoma who undergo nephrectomy [had] no options for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting evidence [prior to this approval]," wrote Toni K. Choueiri, MD, Director of the Ki...
The FDA has approved ropeginterferon alfa-2b-njft (Besremi®, PharmaEssentia) for patients with polycythemia vera, marking the first approval of interferon therapy specifically for patients with polycythemia vera and the first treatment for all patients with polycythemia vera, regardless of their prior treatment history. "Ropeginterferon alfa-2b is a novel long-acting monopegylated IFN-alpha-2b," wrote Heinz Gisslinger, MD, Professor of Hematology at the Medical University of Vienna, Austria, and...
In this recording of Oncology Data Advisor's Live Breast Cancer Panel, three noted experts in breast cancer management partake in a conversation about recent advances in treatment, strategies and integrative medicine modalities to minimize toxicity, and techniques for enabling patients with breast cancer to thrive throughout their diagnosis and treatment.
Anne Chiang, MD, PhD.
Patients with extensive-stage small cell lung cancer (SCLC) are experiencing better survival rates than they have in past years. In honor of Lung Cancer Awareness Month, Anne Chiang, MD, PhD, Chief Integration Officer and Deputy Chief Medical Officer of Smilow Cancer Hospital and Associate Professor in the Section of Medical Oncology at Yale School of Medicine, discusses recent developments that have led to improvements in survival rates, as well as also exciting new developments to come in the treatment of patients with extensive-stage small cell lung cancer.
How can members of the cancer care team enable breast cancer survivors to become breast cancer thrivers? Watch as Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and member of the National Breast Cancer Foundation Medical Advisory Council, explains how to provide optimal care and support for patients with breast cancer during their treatment and beyond.
Within the last few years, treatment of renal cell carcinoma has improved dramatically, with FDA approvals of several agents and numerous others in development. In this interview, Bradley McGregor, MD, Clinical Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School, highlights these exciting developments and sheds light on the additional progress that is underway for the treatment of renal cell carcinoma. Onc...
Oncology Data Advisor™ · Breast Cancer and Pandemic Challenges With Lillie Shockney, RN, BS, MAS, HON-ONN-CG Although the management of breast cancer has been impacted by the COVID-19 pandemic, the cancer care team has developed strategies to optimize screening and treatment experiences in spite of these challenges. In this interview, Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and member of the National Breast Cancer Foundation Medical...
Oncology Data Advisor™ · Applying Precision Medicine in BRAF V600E-Mutant Metastatic Colorectal Cancer Colorectal cancer is the second leading cause of cancer death among men and women in the United States (ACS,2021). An estimated 149,500 new cases are diagnosed annually, and 52,980 people die of the disease (ACS, 2021). When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because colorectal cancer initially exhibits no symptoms and the use...
The survival rate for lung cancer has improved significantly in recent years, largely due to the adoption of biomarker testing and the development of targeted therapies. In this interview in honor of Lung Cancer Awareness Month, Beth Sandy, MSN, CRNP, Outpatient Thoracic Oncology Nurse Practitioner at the University of Pennsylvania Abramson Cancer Center, discusses the importance of utilizing biomarker testing in order to determine treatment options for patients with lung cancer. Oncology Data A...
This latest interview for Breast Cancer Awareness Month features Erin Prendergast, RN, CBCN®, an oncology nurse navigator and Senior Breast Clinical Coordinator in the Breast Cancer Program at UT Southwestern Simmons Comprehensive Cancer Center. Ms. Prendergast explains what she does in her role as an oncology nurse navigator and shares strategies that her team has implemented to ensure that patients with breast cancer receive optimal access to treatment and supportive care during the COVID-19 pandemic.
The FDA has granted accelerated approval to asciminib (Scemblix®, Novartis AG) for patients with Philadelphia chromosome–positive (Ph-positive) chronic myeloid leukemia (CML) who have disease in chronic phase and were previously treated with two or more tyrosine kinase inhibitors and for those whose disease is in chronic phase with the T315I mutation."Patients with CML in chronic phase CML resistant or intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outco...
How can members of the cancer care team help their patients with breast cancer continue to thrive despite their diagnosis? Watch as Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and member of the National Breast Cancer Foundation Medical Advisory Council, shares how to enhance quality of life preservation and restoration for breast cancer patients and survivors.
In this recording of Oncology Data Advisor's Live Breast Cancer Panel, three noted experts partake in a conversation about recent advances in treatment, strategies and integrative medicine modalities to minimize toxicity, and techniques for delivering patient-centered care.
Lillie Shockney, RN, BS, MAS, HON-ONN-CG.
Although the management of breast cancer has been impacted by the COVID-19 pandemic, the cancer care team has developed strategies to optimize screening and treatment experiences in spite of these challenges. In this interview, Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and member of the National Breast Cancer Foundation Medical Advisory Council, shares advice advice regarding protocols for undergoing mammograms during the pandemic, including the timing of COVID-19 vaccination.
For this interview in honor of Breast Cancer Awareness Month, Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and member of the National Breast Cancer Foundation Medical Advisory Council, discusses current standards and recent advances in breast cancer surgery, including lumpectomies, prophylactic mastectomies, and reconstructive procedures.
Lillie Shockney, RN, BS, MAS, HON-ONN-CG.
How can members of the cancer care team enable breast cancer survivors to become breast cancer thrivers? Watch as Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and member of the National Breast Cancer Foundation Medical Advisory Council, explains how to provide optimal care and support for patients with breast cancer during their treatment and beyond.
In this interview, Tricia Trammell, BA, CRA, FAHRA, R.T. (R)(M)(QM)(BS), CN-BI, Breast Center Manager at UT Southwestern Simmons Comprehensive Cancer Center, discusses the advancements in breast imaging in relation to screening for breast cancer.
By accepting you will be accessing a service provided by a third-party external to https://oncdata.com/